HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing

Blood

Volumn 115, Issue 7, 2010, Pages 1354-1363

  Richard, Jonathan ^a,b   Sindhu, Sardar ^a   Pham, Tram N Q ^a   Belzile, Jean Philippe ^a,b   Cohen, Éric A ^a,b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; ULBP 2 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPR PROTEIN; ATR PROTEIN, HUMAN; CELL CYCLE PROTEIN; CELL SURFACE RECEPTOR; IMMUNOLOGIC FACTOR; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA DAMAGE; DRUG ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRESS; T CELL DEPLETION; TARGET CELL; UPREGULATION; VIRION; CELL DEATH; CYTOLOGY; GENETICS; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; KIDNEY; LENTIVIRINAE; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGICAL STRESS; PLASMID; SITE DIRECTED MUTAGENESIS; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE PROTEINS; CELL DEATH; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KILLER CELLS, NATURAL; LENTIVIRUS; LIGANDS; MUTAGENESIS, SITE-DIRECTED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PLASMIDS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CELL SURFACE; STRESS, PHYSIOLOGICAL; UP-REGULATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77949903887     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-237370     Document Type: Article

References (50)

1. Malim MH, Emerman M. HIV-1 accessory proteins: ensuring viral survival in a hostile environment. Cell Host Microbe. 2008;3(6):388-398.
2. Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA. Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem. 1999;274(13):9083-9091. (Pubitemid 29164715)
3. Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L. A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol. 1995;69(11):6873-6879.
4. Hoshino S, Sun B, Konishi M, et al. Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers. AIDS Res Hum Retroviruses. 2007;23(3):391-397. (Pubitemid 46608559)
5. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol. 1995;69(11):6705-6711.
6. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol. 1995;69(10): 6304-6313.
7. Re F, Braaten D, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol. 1995;69(11):6859-6864.
8. Sherman MP, Schubert U, Williams SA, et al. HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology. 2002;302(1):95-105. (Pubitemid 35356858)
9. Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA. Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol. 1999;73(5): 4101-4109. (Pubitemid 29189855)
10. Poon B, Grovit-Ferbas K, Stewart SA, Chen IS. Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science. 1998; 281(5374):266-269. (Pubitemid 28334511)
11. Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, Chen IS. Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol. 1996; 70(4):2516-2524. (Pubitemid 26087618)
12. Stivahtis GL, Soares MA, Vodicka MA, Hahn BH, Emerman M. Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J Virol. 1997;71(6):4331-4338. (Pubitemid 27204120)
13. Zimmerman ES, Sherman MP, Blackett JL, et al. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol. 2006;80(21):10407-10418. (Pubitemid 44628888)
14. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem. 2003;278(28):25879-25886. (Pubitemid 36835349)
15. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog. 2007;3(7):e85.
16. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J. 2007; 4:57. (Pubitemid 47025092)
17. Hrecka K, Gierszewska M, Srivastava S, et al. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A. 2007;104(28):11778-11783. (Pubitemid 47175089)
18. Le Rouzic E, Belaidouni N, Estrabaud E, et al. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle. 2007;6(2):182-188. (Pubitemid 46232499)
19. Schrofelbauer B, Hakata Y, Landau NR. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci U S A. 2007;104(10):4130-4135. (Pubitemid 47181590)
20. Wen X, Duus KM, Friedrich TD, de Noronha CM. The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem. 2007; 282(37):27046-27057.
21. Tan L, Ehrlich E, Yu XF. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol. 2007;81(19): 10822-10830. (Pubitemid 47463356)
22. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186-1190. (Pubitemid 41232299)
23. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3(10): 781-790.
24. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
25. Ward J, Bonaparte M, Sacks J, et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood. 2007;110(4): 1207-1214. (Pubitemid 47281418)
26. Cerboni C, Neri F, Casartelli N, et al. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J Gen Virol. 2007;88(1):242-250. (Pubitemid 46085135)
27. Fogli M, Mavilio D, Brunetta E, et al. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog. 2008; 4(7):e1000101.
28. Lahm HW, Stein S. Characterization of recombinant human interleukin-2 with micromethods. J Chromatogr. 1985;326:357-361.
29. Levesque K, Zhao YS, Cohen EA. Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem. 2003; 278(30):28346-28353. (Pubitemid 36900036)
30. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol. 1995;69(11):7032-7044.
31. Ao Z, Yao X, Cohen EA. Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system. J Virol. 2004;78(6): 3170-3177. (Pubitemid 38314377)
32. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986;59(2):284-291.
33. Kobinger GP, Borsetti A, Nie Z, et al. Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol. 1998;72(7):5441-5448. (Pubitemid 28283325)
34. Bonaparte MI, Barker E. Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS. 2003;17(4):487-494. (Pubitemid 36293101)
35. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004;64(24):9152-9159. (Pubitemid 39665530)
36. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77(21):11708-11717. (Pubitemid 37271669)
37. Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature. 2005; 434(7037):1148-1152. (Pubitemid 40663495)
38. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434(7037): 1093-1097. (Pubitemid 40663481)
39. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 1999; 10(6):661-671. (Pubitemid 29302919)
40. Eckstein DA, Sherman MP, Penn ML, et al. HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med. 2001;194(10):1407-1419.
41. Subbramanian RA, Kessous-Elbaz A, Lodge R, et al. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med. 1998;187(7):1103-1111. (Pubitemid 28176410)
42. Alter G, Teigen N, Davis BT, et al. Sequential de-regulation of NK-cell subset distribution and function starting in acute HIV-1 infection. Blood. 2005; 106(10):3366-3369. (Pubitemid 41609166)
43. Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A. 2003;100(25):15011- 15016. (Pubitemid 37518008)
44. Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A. 2005;102(8):2886- 2891. (Pubitemid 40299886)
45. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908): 734-738. (Pubitemid 35177960)
46. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389-1396. (Pubitemid 36988048)
47. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol. 2005;6(9):928-937.
48. Coudert JD, Zimmer J, Tomasello E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood. 2005;106(5):1711-1717. (Pubitemid 41208585)
49. Salih HR, Holdenrieder S, Steinle A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci. 2008;13:3448-3456.
50. Majumder B, Venkatachari NJ, O'Leary S, Ayyavoo V. Infection with Vpr-positive human immunodeficiency virus type 1 impairs NK-cell function indirectly through cytokine dysregulation of infected target cells. J Virol. 2008;82(14):7189-7200.